A letter from the U.S. Attorney's Office naming a compounding pharmacist as the target of a federal investigation changes the matter overnight. It signals that prosecutors already believe they have enough evidence to treat that specific person as a likely defendant. A pharmacist who instead receives a letter calling them a subject is in a materially different position, and the word the government chooses is not a formality.
Target Status And Subject Status
The Department of Justice defines both terms in the Justice Manual, section 9-11.151, which prosecutors consult before notifying a person ahead of a grand jury proceeding. A target is a person the prosecutor or grand jury already has substantial evidence linking to a crime and, in the prosecutor's own judgment, a putative defendant. A subject is broader and less committal: conduct within the scope of the investigation, without that evidentiary commitment. The letter can accompany, or follow, a grand jury subpoena for pharmacy records covering the same conduct.
Neither label is permanent. A subject can become a target as an investigation develops, and a target's status can shift again before any charge is filed. The designation reflects the government's assessment at the moment the letter is sent, not a fixed outcome.
What Drives A Target Letter In A Compounding Fraud Case
A target letter in a compounding fraud investigation can rest on billing patterns or referral relationships, not only one contested claim. A marketer or prescriber paid for referrals implicates the anti-kickback statute, while compounds billed for ingredient quantities or formulations never dispensed implicate the false claims act civilly and the federal healthcare fraud statute criminally. A pharmacist can receive a target letter individually while a civil investigative demand covering the same conduct is pending against the pharmacy, so the individual and the business can be moving through parallel, differently postured inquiries at once.
The Options After A Target Letter
The letter does not demand an immediate response, but every option that follows is better exercised with counsel already engaged: opening a dialogue with the prosecutor about the scope of the evidence, assessing whether a pre-indictment meeting makes sense, deciding whether grand jury testimony should be sought or avoided, and reviewing what records the pharmacy has already produced. A pharmacist weighing these options is better served by counsel who already handles the firm's broader compounding pharmacy defense work, not counsel encountering the pharmacy's regulatory posture for the first time.
A pharmacist who has also received a facility-level FDA warning letter is managing a separate track with its own response; see FDA Warning Letters to Compounders: The Response That Closes the File for that response, which this article does not repeat.
Health Law Alliance's attorneys have overseen 2,000+ audits and handled 5,000+ matters, with 25+ years of experience.
The Risk Of Speaking With Federal Agents
A pharmacist who receives a target letter retains the Fifth Amendment right to remain silent, and that right does not disappear because an agent is polite or frames the conversation as routine. Agents need not give Miranda-style warnings before an informal interview, and a target letter promises nothing about whether a later conversation stays informal. A false statement to a federal agent, even one not under oath and never written down, can be charged under 18 U.S.C. § 1001, which reaches falsifying, concealing, or covering up a material fact in a matter within federal jurisdiction, and carries up to 5 years in prison. A hallway conversation or an unreturned phone call answered informally can create the same exposure.
A target letter is the government's assessment of the evidence it already has. What a pharmacist says next becomes evidence the government did not have before.
Why Early Legal Counsel Is Critical
It is critical that healthcare providers promptly retain experienced healthcare defense counsel upon receiving a subpoena, target letter, investigative request, or other government inquiry. Early legal intervention can protect the provider's rights, ensure appropriate responses to government requests, avoid inadvertent admissions, preserve relevant defenses, and allow counsel to communicate with investigators on the provider's behalf. Delaying legal representation can significantly affect the outcome of a matter and expose the provider to unnecessary risk, including the separate false-statement exposure described above.
How Health Law Alliance Can Help
Health Law Alliance represents compounding pharmacists from the moment a target letter or grand jury subpoena arrives, before any interview request is answered or any record is produced without counsel's review. The firm's attorneys advise on whether to open a dialogue with the prosecutor, how to preserve records, and how to weigh cooperation against a defense posture given what the government has already shown it has. Contact Health Law Alliance for a free, confidential consultation through its criminal healthcare fraud defense practice.
